Sat Oct 05 03:17:52 UTC 2024: ## AxoGen Receives “Buy” Rating Upgrade: StockNews.com Turns Bullish on Medical Equipment Provider

**New York, NY** – AxoGen (NASDAQ: AXGN), a leading developer and commercializer of nerve regeneration and repair technologies, received a significant boost from analysts at StockNews.com on Friday. The firm upgraded its rating on AxoGen from “Hold” to “Buy,” indicating a positive outlook for the company’s future prospects.

This bullish sentiment is shared by other analysts. Raymond James initiated coverage on AxoGen in July with an “Outperform” rating and a $13.00 price target. JMP Securities raised their price target on the stock to $20.00 in August, maintaining a “Market Outperform” rating. Canaccord Genuity Group also reiterated a “Buy” rating and set a $15.00 price objective in June.

Overall, according to MarketBeat, the stock currently boasts a consensus rating of “Buy” with a consensus target price of $13.80. This positive sentiment is fueled by AxoGen’s recent financial performance, which saw the company exceed analysts’ expectations in its last quarterly earnings report.

AxoGen reported earnings per share of ($0.04) for the quarter, beating analysts’ estimates of ($0.14). Revenue also surpassed expectations, reaching $47.91 million compared to the projected $43.27 million.

Institutional investors are also showing their confidence in AxoGen. BNP Paribas Financial Markets, Price T Rowe Associates Inc. MD, Lazard Asset Management LLC, and Rhumbline Advisers all increased their holdings in the company during recent quarters. New investor Koss Olinger Consulting LLC also acquired a stake in the company.

AxoGen’s focus on innovative technologies for peripheral nerve regeneration and repair continues to drive its growth. The company’s portfolio includes products like Avance Nerve Graft, AxoGuard Nerve Connector, and AxoGuard Nerve Protector, designed to improve patient outcomes and address the challenges of nerve injuries.

With a favorable outlook from analysts and increasing institutional interest, AxoGen appears well-positioned for continued success in the medical equipment market.

Read More